A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Alisertib (Primary) ; Paclitaxel
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 30 Mar 2017 Planned End Date changed from 1 Jun 2016 to 7 Aug 2017.
- 30 Mar 2017 Planned primary completion date changed from 1 Mar 2016 to 7 Aug 2017.
- 11 Oct 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 41st European Society for Medical Oncology Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History